JP5344926B2 - 皮膚及び粘膜の処置のための製品並びにその調製方法 - Google Patents
皮膚及び粘膜の処置のための製品並びにその調製方法 Download PDFInfo
- Publication number
- JP5344926B2 JP5344926B2 JP2008545126A JP2008545126A JP5344926B2 JP 5344926 B2 JP5344926 B2 JP 5344926B2 JP 2008545126 A JP2008545126 A JP 2008545126A JP 2008545126 A JP2008545126 A JP 2008545126A JP 5344926 B2 JP5344926 B2 JP 5344926B2
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- skin
- trichloroacetic acid
- agent
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 27
- 210000004400 mucous membrane Anatomy 0.000 title description 9
- 238000002360 preparation method Methods 0.000 title description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 50
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 29
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
- 206010000496 acne Diseases 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 10
- 208000032544 Cicatrix Diseases 0.000 claims description 9
- 150000007514 bases Chemical class 0.000 claims description 9
- 231100000241 scar Toxicity 0.000 claims description 9
- 230000037387 scars Effects 0.000 claims description 9
- 230000006378 damage Effects 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 208000003351 Melanosis Diseases 0.000 claims description 4
- 230000037390 scarring Effects 0.000 claims description 4
- 206010051246 Photodermatosis Diseases 0.000 claims description 3
- 208000012641 Pigmentation disease Diseases 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 230000004075 alteration Effects 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 230000003139 buffering effect Effects 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 230000000366 juvenile effect Effects 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 3
- 230000008845 photoaging Effects 0.000 claims description 3
- 230000019612 pigmentation Effects 0.000 claims description 3
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 claims description 2
- 229940106681 chloroacetic acid Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000000994 depressogenic effect Effects 0.000 claims description 2
- 210000004195 gingiva Anatomy 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000007665 sagging Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 230000008833 sun damage Effects 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- 208000034493 Mucous membrane disease Diseases 0.000 claims 3
- 201000006082 Chickenpox Diseases 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- 238000005660 chlorination reaction Methods 0.000 claims 1
- 238000001879 gelation Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 29
- 239000000047 product Substances 0.000 description 25
- 210000002615 epidermis Anatomy 0.000 description 17
- 210000004207 dermis Anatomy 0.000 description 15
- 239000010410 layer Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 206010040844 Skin exfoliation Diseases 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- -1 TCA hydrogen ions Chemical class 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229910002024 Aerosil® 200 Pharma Inorganic materials 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical class [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/22—Peroxides; Oxygen; Ozone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
a)適切な量のトリクロロ酢酸(CCl3COOH、TCAとも記す)を準備する工程と、
b)適切な量の過酸化水素(H2O2)を準備する工程と、
c)工程a)のトリクロロ酢酸と、工程b)の過酸化水素との第1の混合物を作成する工程と、
d)前記トリクロロ酢酸を含む前記第1の混合物の緩衝を得ることができる、所定量の塩基性化合物を準備する工程と、
e)緩衝するため、即ち前記トリクロロ酢酸を含む前記第1の混合物のpH値を所望の値にするために、工程d)の塩基性化合物を前記第1の混合物に加える工程と、
を含む方法によって得ることができる。
Claims (19)
- 皮膚及び粘膜の疾患の医療的治療及び/又は美容及び/又は化粧上の処置のための、トリクロロ酢酸、過酸化水素及び塩基性化合物を含む剤を調製する方法であって、
a)適切な量のトリクロロ酢酸(CCl3COOH、TCAとも記す)を準備する工程と、
b)適切な量の過酸化水素(H2O2)を準備する工程と、
c)前記トリクロロ酢酸と前記過酸化水素との第1の混合物を作成する工程と、
d)前記第1の混合物に含まれる前記トリクロロ酢酸の緩衝効果を得ることができる、所定量の塩基性化合物を準備する工程と、
e)前記トリクロロ酢酸CCl3COOHを含む前記第1の混合物を緩衝するために前記塩基性化合物を前記第1の混合物に加える工程と、
を含むことを特徴とする上記剤の調製方法。 - 前記塩基性化合物が、アンモニア、トリエタノールアミンから選択される少なくとも1種の化合物、又はそれらの混合物であることを特徴とする請求項1に記載の方法。
- 得られる前記剤が、2.3〜2.6の間のpHを有することを特徴とする請求項1又は2に記載の方法。
- 前記工程a)において前記トリクロロ酢酸が実質的に純粋な状態で提供されることを特徴とする請求項1〜3のいずれかに記載の方法。
- 前記工程a)の前記トリクロロ酢酸が、酢酸かクロロ酢酸又はそれらの混合物の塩素化の工程によって得られることを特徴とする請求項1に記載の方法。
- 前記第1の混合物中の前記トリクロロ酢酸が15〜50%w/wの範囲の濃度であることを特徴とする請求項1〜5のいずれかに記載の方法。
- 前記第1の混合物中の前記トリクロロ酢酸が25〜40%w/wの範囲の濃度であることを特徴とする請求項1〜5のいずれかに記載の方法。
- 前記第1の混合物中の前記トリクロロ酢酸が30〜35%w/wの範囲の濃度であることを特徴とする請求項1〜5のいずれかに記載の方法。
- 前記第1の混合物中の前記トリクロロ酢酸が33%w/wの濃度であることを特徴とする請求項1〜5のいずれかに記載の方法。
- 前記第1の混合物中の前記過酸化水素が85〜50%w/wの範囲の濃度であることを特徴とする請求項1〜9のいずれかに記載の方法。
- 前記第1の混合物中の前記過酸化水素が75〜60%w/wの範囲の濃度であることを特徴とする請求項1〜9のいずれかに記載の方法。
- 前記第1の混合物中の前記過酸化水素が70〜65%w/wの範囲の濃度であることを特徴とする請求項1〜9のいずれかに記載の方法。
- 前記第1の混合物中の前記過酸化水素が67%w/wの濃度であることを特徴とする請求項1〜9のいずれかに記載の方法。
- 工程e)の後に、増粘剤を用いてゲル化する工程をさらに含むことを特徴とする請求項1〜13のいずれかに記載の方法。
- 得られる前記ゲル化された剤のpH値が、ゲル化前の剤のpH値よりも高いことを特徴とする請求項14に記載の方法。
- 得られる前記ゲル化された剤のpH値が5〜6の範囲であることを特徴とする請求項15に記載の方法。
- 請求項1〜16のいずれかに記載の方法によって得られた、皮膚及び粘膜の疾患の医療的治療のための剤。
- 皮膚及び粘膜の疾患が、座瘡、若年性にきび、座瘡の結果生じる瘢痕、若年性にきびの結果生じる瘢痕、水痘の結果生じる瘢痕、太陽光による損傷、太陽光によるそばかす、前癌性の病変、色素沈着トラブル、新しい陥没性瘢痕に由来する損傷、歯肉を含む体の全ての部位の瘢痕の萎縮、肥大、退縮及び変質、老化による損傷、皮膚の光老化、しわ、皮膚のたるみ、または胸の垂れ下がりである請求項17に記載の剤。
- クリーム、軟膏、液体、ゲル、又は噴霧剤の形態である請求項17又は18に記載の剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000211A ITUD20050211A1 (it) | 2005-12-13 | 2005-12-13 | Prodotto per il trattamento della pelle relativo procedimento di preparazione |
ITUD2005A000211 | 2005-12-13 | ||
PCT/IB2006/003558 WO2007069024A2 (en) | 2005-12-13 | 2006-12-12 | Product for treating the skin and mucous membranes, and relative method of preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009519315A JP2009519315A (ja) | 2009-05-14 |
JP5344926B2 true JP5344926B2 (ja) | 2013-11-20 |
Family
ID=36658741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008545126A Active JP5344926B2 (ja) | 2005-12-13 | 2006-12-12 | 皮膚及び粘膜の処置のための製品並びにその調製方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US10874883B2 (ja) |
EP (1) | EP1979053B1 (ja) |
JP (1) | JP5344926B2 (ja) |
AU (1) | AU2006325083B2 (ja) |
CY (1) | CY1114888T1 (ja) |
DK (1) | DK1979053T3 (ja) |
ES (1) | ES2441440T3 (ja) |
HR (1) | HRP20140063T1 (ja) |
IT (1) | ITUD20050211A1 (ja) |
PL (1) | PL1979053T3 (ja) |
PT (1) | PT1979053E (ja) |
SI (1) | SI1979053T1 (ja) |
WO (1) | WO2007069024A2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2930727B1 (fr) * | 2008-04-30 | 2012-10-05 | Evolution Dermatologique Lab | Composition pour le traitement des etats seborrheiques. |
DK2407151T3 (da) * | 2010-07-15 | 2019-12-02 | Progressare Medinvest B V | Sammensætning til behandling af hud- og/eller neglelæsioner |
IT201600111171A1 (it) * | 2016-11-04 | 2018-05-04 | Uras Cosmetics S R L S | Kit per il trattamento della pelle e suo impiego |
IT201700104536A1 (it) * | 2017-09-19 | 2019-03-19 | Cmed Aesthetics Srl | Prodotti topici con sistema bifasico |
CN116528846A (zh) | 2020-12-01 | 2023-08-01 | 罗萨纳·卡斯特拉纳 | 用于皮肤和粘膜的创伤性损伤愈合的制剂 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1216999A (en) * | 1968-04-05 | 1970-12-23 | Petrocarbon Dev Ltd | Improvements in or relating to the production of percarboxylic acids |
US5166176A (en) | 1986-12-29 | 1992-11-24 | Obagi Zein E | Composition for healing damaged skin |
US4874361A (en) * | 1986-12-29 | 1989-10-17 | Obagi Zein E | Method for healing damaged skin |
US5259888A (en) * | 1992-02-03 | 1993-11-09 | Sachem, Inc. | Process for cleaning quartz and silicon surfaces |
JPH0728192A (ja) * | 1993-07-08 | 1995-01-31 | Konica Corp | ハロゲン化銀写真感光材料 |
JP2857042B2 (ja) * | 1993-10-19 | 1999-02-10 | 新日本製鐵株式会社 | シリコン半導体およびシリコン酸化物の洗浄液 |
JP3040307B2 (ja) * | 1994-04-12 | 2000-05-15 | 新日本製鐵株式会社 | 蒸気洗浄方法 |
IT1274157B (it) | 1994-09-08 | 1997-07-15 | Avantgarde Spa | "sale della l-carnitina e composizioni farmaceutiche che lo contengonoper il trattamento di affezioni cutanee" |
WO1996023490A1 (en) | 1995-02-03 | 1996-08-08 | Cosmederm Technologies | Formulations and methods for reducing skin irritation |
US5827884A (en) | 1995-09-15 | 1998-10-27 | Omp Acquisition Corporation | Skin peel maintenance composition and method |
WO2002072018A2 (en) * | 2001-03-09 | 2002-09-19 | R.F. Technology Consultants, Inc. | A cream-t0-powder dermatological composition |
KR101183075B1 (ko) * | 2002-07-01 | 2012-09-20 | 빌라니 마리아 | 피부 질환의 치료 및 예방을 위한 해면동물 유래의 치료조성물 |
US20040101571A1 (en) | 2002-09-11 | 2004-05-27 | Pamela Reed | Use of hydrogen peroxide for the treatment of warts |
JP4241821B2 (ja) * | 2003-02-24 | 2009-03-18 | ビーエーエスエフ ソシエタス・ヨーロピア | 金属表面処理用カルボキシレート含有ポリマー |
US7479133B2 (en) * | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating acne and rosacea with galvanic generated electricity |
JP5548329B2 (ja) * | 2003-08-04 | 2014-07-16 | 杏林製薬株式会社 | 経皮吸収型製剤 |
US7465408B1 (en) * | 2003-12-03 | 2008-12-16 | Advanced Micro Devices, Inc. | Solutions for controlled, selective etching of copper |
JP2005281133A (ja) * | 2004-03-26 | 2005-10-13 | Shiseido Co Ltd | 皮膚外用剤 |
-
2005
- 2005-12-13 IT IT000211A patent/ITUD20050211A1/it unknown
-
2006
- 2006-12-12 US US12/086,453 patent/US10874883B2/en active Active
- 2006-12-12 PL PL06831681T patent/PL1979053T3/pl unknown
- 2006-12-12 ES ES06831681.9T patent/ES2441440T3/es active Active
- 2006-12-12 SI SI200631725T patent/SI1979053T1/sl unknown
- 2006-12-12 WO PCT/IB2006/003558 patent/WO2007069024A2/en active Application Filing
- 2006-12-12 EP EP06831681.9A patent/EP1979053B1/en active Active
- 2006-12-12 AU AU2006325083A patent/AU2006325083B2/en active Active
- 2006-12-12 JP JP2008545126A patent/JP5344926B2/ja active Active
- 2006-12-12 DK DK06831681.9T patent/DK1979053T3/da active
- 2006-12-12 PT PT68316819T patent/PT1979053E/pt unknown
-
2014
- 2014-01-20 HR HRP20140063TT patent/HRP20140063T1/hr unknown
- 2014-01-22 CY CY20141100055T patent/CY1114888T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1979053B1 (en) | 2013-10-23 |
AU2006325083A1 (en) | 2007-06-21 |
HRP20140063T1 (hr) | 2014-02-28 |
PT1979053E (pt) | 2014-01-07 |
WO2007069024A3 (en) | 2007-10-04 |
EP1979053A2 (en) | 2008-10-15 |
DK1979053T3 (da) | 2014-01-20 |
JP2009519315A (ja) | 2009-05-14 |
SI1979053T1 (sl) | 2014-02-28 |
AU2006325083B2 (en) | 2012-03-15 |
ITUD20050211A1 (it) | 2007-06-14 |
ES2441440T3 (es) | 2014-02-04 |
US10874883B2 (en) | 2020-12-29 |
CY1114888T1 (el) | 2016-12-14 |
WO2007069024A2 (en) | 2007-06-21 |
PL1979053T3 (pl) | 2014-04-30 |
US20090110646A1 (en) | 2009-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3821370A (en) | Topical composition for treating seborrheic keratosis | |
CA2931564C (en) | Composition, system and method for treating skin | |
KR20040006007A (ko) | 산성 외용 조성물 및 이것을 포함하는 화장료, 육모제, 외용제용의 피부 등에의 침투 촉진제 | |
JP5344926B2 (ja) | 皮膚及び粘膜の処置のための製品並びにその調製方法 | |
US20110236503A1 (en) | Topical Skincare Composition | |
KR20060019540A (ko) | 경피 투여용 국소 조성물 | |
WO1995016454A1 (en) | Method for treatment of papulo-pustules and comedones of the skin | |
Wambier et al. | Combining phenol-croton oil peel | |
CA2683769C (en) | Composition for removing a tattoo | |
NO328596B1 (no) | Ikke-terapeutisk fremgangsmate for a forbedre huden | |
RU2826643C2 (ru) | Композиции для одонтологического и дерматологического применения, содержащие трихлорацетатные соли и гидроксикислоты | |
CN112791093A (zh) | 治疗痤疮的透皮给药组合物及其制备方法 | |
RU2817870C1 (ru) | Композиция для пилинга кожи | |
AU2020303190A1 (en) | Formulations for odontological and dermatological use containing trichloroacetate salts and hydroxyacids | |
TW202214221A (zh) | 齒科學及皮膚學使用之含有三氯乙酸鹽及羥酸之配方 | |
WO2022087219A9 (en) | Skin treatment compositions and methods | |
CA3091879A1 (en) | Regenerating composition with smoothing action for treating skin imperfections and process for preparation thereof | |
TWI325324B (ja) | ||
MX2007006059A (es) | Composicion de crema desmanchadora de piel. | |
Liapakis et al. | Clinicopathological Aspects and Risks of the Phenol Croton Oil Peel | |
JP2002029958A (ja) | 皮膚化粧料 | |
NZ721272B2 (en) | Composition, system and method for treating skin | |
NZ759509B2 (en) | Composition, system and method for treating skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120710 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121009 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121016 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121109 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121210 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121217 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130326 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130614 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130730 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130813 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5344926 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D03 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |